Delivery Order SPE2DB22D3501-SPE2DB26FTH49
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $6,837.84 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 26, 2025, with completion scheduled for August 27, 2025. This competitively awarded, firm fixed-price delivery order represents a single transaction under AmerisourceBergen's larger pharmaceutical supply contract vehicle with DLA. The product will be delivered to the company's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $14,595.53 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on October 30, 2025, with an ultimate completion date of October 31, 2025. This non-competitive, firm fixed-price delivery order will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to the federal...
- The Defense Logistics Agency awarded a delivery order valued at $54,265.48 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on September 11, 2025, with an ultimate completion date of September 12, 2025. This firm fixed-price contract, which carries no set-aside designation, represents a competitively awarded procurement under the company's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The delivery order will be fulfilled from...
- The Defense Logistics Agency awarded a delivery order valued at $17,061.95 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on September 25, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and is scheduled for completion by September 26, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $12,949.95 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors (2 mL units). This is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and represents a non-set-aside award. The products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $16,998.05 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 14, 2025, with completion scheduled for July 15, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The delivery is scheduled to occur at AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $25,982.33 on August 21, 2025, for the supply of Dupixent 200 mg/1.14 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of August 22, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $54,946.51 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 3, 2025, with an ultimate completion date of July 7, 2025. This firm fixed-price delivery order carries no set-aside designation and represents a competitively awarded transaction under the company's existing indefinite delivery contract with DLA Troop Support Medical. The place of performance is AmerisourceBergen's corporate office in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $350,241.69 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors. This firm fixed-price delivery order, issued on September 27, 2025, is set to be completed by September 29, 2025, with performance occurring at the contractor's facility in Conshohocken, Pennsylvania. The award represents a competitive procurement with no set-aside designation, reflecting AmerisourceBergen's demonstrated capability...
- The Defense Logistics Agency awarded a $64,924.28 delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on October 30, 2025, with a completion date of October 31, 2025. This competitively awarded, firm fixed price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The company's corporate office location in...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB26FTH49Delivery Order
The Defense Logistics Agency awarded a $56,299.22 delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors. The contract, awarded on October 29, 2025, with an ultimate completion date of October 30, 2025, represents a firm fixed-price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor for this pharmaceutical supply requirement, which will be fulfilled at their corporate office location. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The IDC functions as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of medications and medical supplies to support military healthcare programs worldwide. Dupixent is a specialty biologic medication used in the treatment of various inflammatory conditions, reflecting AmerisourceBergen's role as a critical vendor for specialized pharmaceutical products serving the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $56.3k | 10/29/25 |